A new treatment for Alzheimer’s could halt deterioration in people with early symptoms of the disease, a limited human trial has shown. The treatment, called the
most exciting drug in development by scientists, is currently prescribed to people with immune system problems but could have a significant impact on the quality of life of Alzheimer’s sufferers, the trial suggests.
The drug, intravenous immunoglobulin (IVIg), prevented the decline in cognitive skills, memory and the ability to live independently, among patients with mild to moderate symptoms of Alzheimer’s. Those who took a placebo continued to decline. The small number of patients who took the highest dose of the drug for three years showed no decline in memory.
Medical experts said the drug could be used to treat Alzheimer’s within a decade and was
probably the most exciting drug we know about that is currently in the late stages of research — via redwolf.newsvine.com